Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q1 FY2027 Earnings Presentation
9 slides from Phibro Animal Health's earnings presentation, Nov 5, 2026
Slide 1: Webcast and Conference Call: Financial Results Fiscal Year 2027 First Quarter
Phibro Animal Health Corporation Webcast and Conference Call November 5, 2026 U.S. toll-free +1.833.461.5787 International toll +1.585.542.9983 Conference ID: 646434646 Financial Results Fiscal Year 2027 First Quarter Ended September 30, 2026 November 5, 2026 Webcast and Conference Call
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or cur
Slide 3: Key Themes
Key Themes Q1 Sales Animal Health Business Updates FY2027 Full Year Highlights Performance Guidance Q1 Total Consolidated sales and Q1 Total Animal Health sales and Plans on track to close site acquired as Maintained 2027 guidance adjusted EBITDA growth of 6% and 4% adjusted EBITDA growth of 3% and
Slide 4: Financial Performance - Consolidated
Financial Performance - Consolidated First Quarter, Year-on-Year comparison $ in millions, except per share data Q1 Q1 YOY FY26 FY27 %∆ Consolidated Net Sales $ 363.9 $ 386.8 6% Net Income $ 26.5 $ 29.5 11% Diluted EPS $ 0.65 $ 0.72 11% Adjusted EBITDA $ 61.9 $ 64.3 4% Adjusted Net Income $ 29.8 $ 3
Slide 5: Financial Performance – Animal Health
Financial Performance – Animal Health First Quarter, Year-on-Year comparison $ in millions Q1 Q1 YOY FY26 FY27 %∆ Animal Health Net Sales $ 283.5 $ 293.0 3% MFAs & other 195.2 206.5 6% Nutritional specialties 48.2 47.1 (2%) Vaccines 40.1 39.5 (2%) Adj. EBITDA $ 74.9 $ 73.9 (1%) Adj. EBITDA Margin 26
Slide 6: Financial Performance – Other Segments
Financial Performance – Other Segments First Quarter, Year-on-Year comparison $ in millions Q1 Q1 YOY FY26 FY27 %∆ Mineral Nutrition Net Sales $ 63.0 $ 73.6 17% Adj. EBITDA $ 4.5 $ 6.2 36% Adj. EBITDA Margin 7.2% 8.4% +120 bps Performance Products Net Sales $ 17.4 $ 20.2 16% Adj. EBITDA $ 1.6 $ 2.8
Slide 7: Key Capitalization Metrics
Key Capitalization Metrics September 30, 2026 Free cash flow was $22 million for the TTM -- positive cash from operating activities Free Cash Flow (1) of $86 million, less capital expenditures of $(64) million. Cash and cash equivalents of $83 million 2.9x gross leverage ratio; $740 million total de
Slide 8: Financial Guidance – Phibro
Financial Guidance – Phibro Fiscal Year 2027 $ in millions, except earnings per share (EPS) data FY 2026 FY 2027 Maintained Guidance Actual Low High Consolidated Net Sales $ 1,518 $ 1,550 $ 1,600 Net Income $ 100 $ 122 $ 132 Diluted EPS $ 2.43 $ 2.98 $ 3.22 Adjusted EBITDA $ 255 $ 258 $ 268 Adjusted
Slide 9: Q&A
PAHC Company Overview Q&A 9 November 5, 2026 Webcast and Conference Call
Phibro Animal Health — Q1 FY2027 Earnings Presentation on 6ix